Share on Facebook
Share on Twitter
Share on LinkedIn

Pharmaceutical companies, medical device makers and academic medical centers would no longer be able to withhold the results of clinical trials under rules proposed by the U.S. Department of Health and Human Services.

While millions of Americans participate in trials of experimental drugs and devices to help find new treatments for themselves and others, the findings often aren’t made public, said Harlan Krumholz, a cardiologist and health policy professor Yale University in New Haven, Connecticut, and head of the Yale-New Haven Hospital Center for Outcomes Research and Evaluation.

Click here to read more.